MDS Pharma Expands Drug Discovery Capability In Asia

MDS Pharma has announced that renovation and expansion of its discovery pharmacology operation in Taiwan is under way, to serve the growing global demand for work performed in Asia.

The renovation and expansion will be completed in 2010. The drug discovery capability is aligned with the new MDS Pharma Services’ strategic focus on early stage operations.

The Taiwan facility supports both molecular screening and profiling, as well as in vivo safety and efficacy testing. In vivo capacity has been doubled, and will include dedicated space tailored to individual client needs. Furthermore, the site’s automated molecular screening and profiling capability and efficiency will be improved with additional robotic high-throughput screening capacity and analytical support.

David Spaight, President, MDS Pharma, said: This new and expanded facility will cement our position as the global leader in the discovery pharmacology space. This investment builds on a 40-year track record of success in this service area, and supports our recently announced strategic focus on the Discovery through Phase IIa Proof-of-Concept segment of the outsourcing market.